Ricardo Gonzalez Balboa Appointed as General Manager of Eisai Laboratorios, S. de R.L. de C.V.

Ricardo Gonzalez Balboa Appointed as General Manager of Eisai Laboratorios, S.
                               de R.L. de C.V.

Will Lead Commercial Strategy for Eisai's Subsidiary in Mexico

PR Newswire

WOODCLIFF LAKE, N.J., May 16, 2013

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ --Eisai Inc., the U.S.
pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment
of Ricardo Gonzalez Balboa to the position of General Manager, Eisai
Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a direct subsidiary of Eisai
Inc. In this position, Mr. Gonzalez Balboa will further develop and implement
the company's commercial strategy in Mexico.

(Photo: http://photos.prnewswire.com/prnh/20130516/NY11800 )

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

Since its establishment in 2011, Eisai Mexico has filed several products with
the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) for
regulatory review. Eisai Mexico is focusing on further development of its
operations in preparation for the introduction of these products, supporting
Eisai's human health care (hhc) mission to satisfy unmet medical needs and
contribute to the health and well-being of people worldwide.

Under Mr. Gonzalez Balboa's leadership, Eisai Mexico will continue to
establish productive relationships with key constituents in Mexico's
healthcare system and ensure compliance of sales and marketing practices with
all applicable regulations and laws.

"We are very pleased to have Ricardo on the ground in Mexico to help build
Eisai's capabilities there, and bring our company's products to patients in
the region," said Douglas Calandra, Vice President of Latin America, Eisai
Inc. "Ricardo possesses the business competencies critical for success in this
role, and also has a passion for creating patient value. We are confident that
he is the right leader to build our Mexican organization, and to help further
our human health care mission within this important country."

Mr. Gonzalez Balboa comes to Eisai from Bayer Health Care, where he headed the
Specialty Medicine and Institutional Business for the company's Mexican
operations. In addition to leading marketing strategy and promotion for
several products there, he oversaw access and pharmaco-economics functions.

Prior to Bayer, Mr. Gonzalez Balboa spent ten years with Roche in Mexico,
where he attained roles of increasing responsibility in various functions,
including oncology, metabolism, respiratory, hematology, business development
and market research. His most recent role there was oncology director. Prior
to Roche, he held financial analyst and business planning positions with
Bristol-Myers Squibb's Mexican operations.

Eisai Laboratorios, S. de R.L. de C.V.

Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a wholly owned
subsidiary of Eisai Inc., is Eisai's commercial operation in Mexico. The
company was established in 2011 and is based in Mexico City.

Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that
discovers, develops and markets products throughout the world. Through a
global network of research facilities, manufacturing sites and marketing
subsidiaries, Eisai actively participates in all aspects of the worldwide
healthcare system.

Media Inquiries      Investor Inquiries
Lisa Wolfe           Alex Scott
Eisai Inc.           Eisai Inc.
201-746-2959         201-746-2177

SOURCE Eisai Inc.

Website: http://www.eisai.com
Press spacebar to pause and continue. Press esc to stop.